News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Outlook Therapeutics' CFO, Lawrence A. Kenyon, purchased 101,010 shares of common stock and 101,010 accompanying warrants in an underwritten public offering on August 14, 2026. The combined offering price was $0.99 per share and warrant, with the warrants immediately exercisable at $1.10 and expiring …
Outlook Therapeutics (OTLK) stock has seen a significant decline over the past five years, despite the recent FDA approval and upcoming launch of LYTENAVA. The company's valuation scores poorly, indicating it's not a bargain, and its balance sheet shows a negative book value, making …
Outlook Therapeutics (OTLK) stock has declined significantly over the past five years, yet recent valuation checks do not indicate it is a clear bargain. The company's negative shareholder equity makes its Price-to-Book (P/B) ratio unreliable for valuation, and despite the recent approval of LYTENAVA …
Outlook Therapeutics CEO Robert Jahr recently acquired 151,515 shares of common stock and an equal number of warrants. This transaction occurred at a combined public offering price of $0.99 per unit, amounting to $0, with each warrant allowing the purchase of one share at …
Outlook Therapeutics (OTLK) CEO Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026. The transaction occurred in an underwritten public offering at a combined price of $0.99 per share and warrant. The warrants are exercisable immediately …
J. Goldman & Co., L.P. and related entities have reported a 6.11% beneficial ownership stake in Grocery Outlet Holding Corp. (GO), as detailed in a Schedule 13G filing. This position comprises 6,040,848 shares of common stock, which includes 1,240,100 shares issuable upon the exercise …
Outlook Therapeutics, Inc. (OTLK) reported a Q3 loss of $0.09 per share, aligning with analyst expectations, but missed revenue estimates significantly with $0.01 million compared to an expected $1.5 million. The company's stock has underperformed the S&P 500 this year, and while the current …
Kayne Anderson Rudnick Investment Management, LLC has filed an amended beneficial ownership report for Ollie's Bargain Outlet Holdings Inc (OLLI), disclosing a 1.6% beneficial stake. The firm owns 974,819 shares of common stock as of June 30, 2026, with detailed allocations for sole and …
Outlook Therapeutics reported its third-quarter fiscal year 2026 financial results, highlighting the FDA approval of LYTENAVA™ for wet age-related macular degeneration (wet AMD). The company is preparing for a U.S. commercial launch by the end of 2026, with an estimated potential to exceed $500 …
Outlook Therapeutics (OTLK) reported a Q3 fiscal 2026 net loss of $20.3 million but highlighted the FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet age-related macular degeneration, the only FDA-approved ophthalmic bevacizumab for this condition. The company is preparing for a U.S. launch by year-end …
Wedge Capital Management L L P NC significantly increased its stake in Unitil Corporation, purchasing an additional 24,131 shares, bringing its total holdings to 51,839 shares valued at $2.7 million. Other institutional investors also adjusted their positions in Unitil, which reported strong quarterly earnings …
Grocery Outlet (GO) stock jumped 6% after its Q2 earnings showed adjusted EPS and EBITDA ahead of outlook, suggesting an early turnaround. Despite this, the company faces ongoing challenges including declining same-store sales and a significant debt load of US$506 million. The market is …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Grocery Outlet Holding (GO) shares reacted to fresh earnings news after the company reported second quarter results that topped revenue and earnings expectations, raised the lower end …
Key Points Grocery Outlet's turnaround strategy is taking hold. Same-store sales are edging toward positive.10 stocks we like better than Grocery Outlet › Shares of Grocery Outlet (NASDAQ: GO) rose on Thursday after the discount retailer raised its full-year sales and profit forecast. Image …
Grocery Outlet (GO) Stock Trades Up, Here Is Why What Happened? Shares of discount grocery store chain Grocery Outlet (NASDAQ:GO) jumped 8.8% in the afternoon session after the discount grocer reported second-quarter fiscal 2026 results that beat analyst expectations and raised its full-year financial …
Grocery Outlet reported strengthened business stabilization and growth in Q2, with net sales increasing by 1.1% to $1.19 billion despite a slight decline in comparable-store sales. The company's efforts to enhance its opportunistic offerings and improve sourcing contributed to this momentum, leading to a …
Grocery Outlet (GO) reported strong second-quarter 2026 results, surpassing Zacks Consensus Estimates for both net sales and adjusted earnings per share. The company saw sequential improvements in comparable-store sales and customer basket trends, leading management to raise its fiscal 2026 outlook for net sales, …
Outlook Therapeutics Inc. (OTLK) stock is plummeting due to its announcement of a public offering of 55.6 million shares and accompanying warrants at a significant discount, causing substantial dilution for existing shareholders. The capital raise aims to fund the commercial launch of LYTENAVA, its …
Telsey has increased its price target for Grocery Outlet Holding (NASDAQ:GO) to $12.00 from $9.00, maintaining a Market Perform rating, due to better-than-expected Q2 2026 results and raised full-year guidance. The company reported adjusted EPS of $0.20 against a forecast of $0.13, and showed …
D.A. Davidson increased its price target for Grocery Outlet Holding (NASDAQ:GO) to $12.00 from $9.00, maintaining a Neutral rating, following the company's strong second-quarter performance and increased 2026 guidance. Telsey Advisory Group also raised its price target to $12.00. The firm cited reduced earnings …
Outlook Therapeutics (OTLK [https://seekingalpha.com/symbol/OTLK]) shares fell nearly 15% in premarket trading Thursday after the company priced a public offering of 55.6M shares and warrants for gross proceeds of about $55M. The combined offering price is $0.99 per share and accompanying warrant, with the warrants …
Search by ticker symbol or company name and select a result to open its chart.